PARP Inhibitor Market Dynamics: A Podcast
Datamonitor Healthcare analysts discuss Lynparza, Zejula, Rubraca, Talzenna and veliparib
PARP inhibitors are expected to generate $10bn in sales by 2030. Datamonitor Healthcare analysts discuss their positioning in breast, ovarian, pancreatic and prostate cancer, looking at the current market landscape and future strategies.
You may also be interested in...
Metastatic prostate cancer continues to evade the checkpoint inhibitor class but Merck is not giving up on an area where overall survival remains limited.
One of two PARP inhibitors approved in breast cancer, Lynparza may have the adjuvant breast indication all to itself for a while. One analyst projects a $1.5bn revenue opportunity for the indication.
AstraZeneca and Merck & Co’s latest results put them far ahead of competitors in prostate cancer in reaching patient regardless of their mutational status.